NU Skin Enterprises, Inc. NUS
Other Pharmaceuticals · IPO 1996 · data as of November 13, 2026
NU Skin Enterprises, Inc. (NUS) is a healthcare company listed in the US with a market value of about $196M. In the twelve months to September 30, 2026 it had revenue of $1.3B and net income of -$234M, a net margin of -17.7%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 29% below the current price.
About NU Skin Enterprises
NU Skin Enterprises is listed in the US and classified in other pharmaceuticals, IPO year 1996. Revenue went from $2.6B in 2014 to $1.5B in 2025, a decline of about 4.9% a year. It was profitable in 9 of the last 10 years in our data. It spends 1% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Profit margin improving
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Pays a dividend
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.5B | $1.7B | $2.0B | $2.2B | $2.7B | $2.6B | $2.4B | $2.7B | $2.3B | $2.2B |
| Net income | -$234M | $160M | -$147M | $9M | $105M | $147M | $191M | $174M | $122M | $129M | $143M |
| Free cash flow | -$26M | $46M | $70M | $60M | $49M | $73M | $315M | $112M | $132M | $242M | $225M |
| EPS (diluted) | $-4.85 | $3.18 | $-2.95 | $0.17 | $2.07 | $2.86 | $3.63 | $3.10 | $2.16 | $2.36 | $2.55 |
| Net margin | -17.7% | 10.8% | -8.5% | 0.4% | 4.7% | 5.5% | 7.4% | 7.2% | 4.5% | 5.7% | 6.5% |
| ROIC | — | 4.9% | -11.3% | 2.7% | 6.2% | 10.5% | 13.9% | 13.1% | 11.0% | 19.6% | 14.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is NU Skin Enterprises stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 29% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does NU Skin Enterprises pay a dividend?
Yes. The dividend yield is about 5.92%, and it has paid dividends for 10 years in our data.
Is NU Skin Enterprises a good stock to buy?
We do not give buy or sell advice. NU Skin Enterprises scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.